Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

The FDA has approved EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) for first-line use in locally advanced and ...

It was alleged Tottenham failed to ensure their spectators and/or supporters conducted themselves in an orderly fashion and did not use words or otherwise behave in an improper, offensive ...